Anne Koy

Anne Koy

Auto-generated profile, based on publicly available information

Anne Koy

Department of Pediatrics, Faculty of Medicine and University Hospital Cologne University of Cologne Cologne Germany

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2013 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
AKAnne Koy
Anne Koy
MHMartin Hellmich
Martin Hellmich
KPK. Amande M. Pauls
K. Amande M. Pauls
WMWarren Marks
Warren Marks
JLJean‐Pierre Lin
Jean‐Pierre Lin
LTLars Timmermann
Lars Timmermann

1 June 2016 in The Lancet Neurology
Verified
Journal Article
Closed access
AKAnne Koy
Anne Koy
JLJean-Pierre Lin
Jean-Pierre Lin
TSTerence D Sanger
Terence D Sanger
WMWarren A Marks
Warren A Marks
JMJonathan W Mink
Jonathan W Mink
LTLars Timmermann
Lars Timmermann

1 August 2018 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
AKAnne Koy
Anne Koy
SCSebahattin Cirak
Sebahattin Cirak
VGVictoria Gonzalez
Victoria Gonzalez
KBKerstin Becker
Kerstin Becker
TRThomas Roujeau
Thomas Roujeau
LCLaura Cif
Laura Cif

1 January 2017 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
AKAnne Koy
Anne Koy
LTLars Timmermann
Lars Timmermann

29 December 2021 in Movement Disorders
Verified
Journal Article
Open access
PDF file
AKAnne Koy
Anne Koy
AKAndrea A. Kühn
Andrea A. Kühn
JHJulius Huebl
Julius Huebl
GSGerd‐Helge Schneider
Gerd‐Helge Schneider
ARAnne K. van Riesen
Anne K. van Riesen
TIthe STIM‐CP investigators
the STIM‐CP investigators
Background: Patients with dyskinetic cerebral palsy are often severely impaired with limited treatment options. The effects of deep brain stimulation (DBS) are less pronounced than those in inherited dystonia but can be associated with favorable quality of life outcomes even in patients without changes in dystonia severity.Objective: The aim is to assess DBS effects in pediatric patients with pharmacorefractory dyskinetic cerebral palsy with focus on quality of life.Methods: The method used is a prospective, single‐arm, multicenter study. The primary endpoint is improvement in quality of life (CPCHILD [Caregiver Priorities & Child Health Index of Life with Disabilities]) from baseline to 12 months under therapeutic stimulation. The main key secondary outcomes are changes in Burke‐Fahn‐Marsden Dystonia Rating Scale, Dyskinesia Impairment Scale, Gross Motor Function Measure‐66, Canadian Occupational Performance Measure (COPM), and Short‐Form (SF)‐36. After 12 months, patients were randomly assigned to a blinded crossover to receive active or sham stimulation for 24 hours each. Severity of dystonia and chorea were blindly rated. Safety was assessed throughout. The trial was registered at ClinicalTrials.gov, number NCT02097693.Results: Sixteen patients (age: 13.4 ± 2.9 years) were recruited by seven clinical sites. Primary outcome at 12‐month follow‐up is as follows: mean CPCHILD increased by 4.2 ± 10.4 points (95% CI [confidence interval] –1.3 to 9.7; P = 0.125); among secondary outcomes: improvement in COPM performance measure of 1.1 ± 1.5 points (95% CI 0.2 to 1.9; P = 0.02) and in the SF‐36 physical health component by 5.1 ± 6.2 points (95% CI 0.7 to 9.6; P = 0.028). Otherwise, there are no significant changes.Conclusion: Evidence to recommend DBS as routine treatment to improve quality of life in pediatric patients with dyskinetic cerebral palsy is not yet sufficient. Extended follow‐up in larger cohorts will determine the impact of DBS further to guide treatment decisions in these often severely disabled patients. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society

22 May 2019 in Human Genome Variation
Verified
Journal Article
Open access
PDF file
RSRosanne Sprute
Rosanne Sprute
DADidem Ardicli
Didem Ardicli
KOKader Karli Oguz
Kader Karli Oguz
AMAnna Malenica-Mandel
Anna Malenica-Mandel
HDHülya-Sevcan Daimagüler
Hülya-Sevcan Daimagüler
SCSebahattin Cirak
Sebahattin Cirak
Asparagine synthetase deficiency (ASNSD, OMIM #615574) is a rare autosomal recessive neurometabolic inborn error that leads to severe cognitive impairment. It manifests with microcephaly, intractable seizures, and progressive cerebral atrophy. Currently, there is no established treatment for this condition. In our pediatric cohort, we discovered, by whole-exome sequencing in two siblings from Turkey, a novel homozygous missense mutation in asparagine synthetase at NM_133436.3 (ASNS_v001): c.1108C>T that results in an amino acid exchange p.(Leu370Phe), in the C-terminal domain. After identification of the metabolic defect, treatment with oral asparagine supplementation was attempted in both patients for 24 months. Asparagine supplementation was well tolerated, and no further disease progression was observed during treatment. One of our patients showed mild developmental progress with increased levels of attention and improved nonverbal communication. These results support our hypothesis that asparagine supplementation should be further investigated as a treatment option for ASNSD. We further reviewed all previously reported ASNSD cases with regard for their clinical phenotypes and brain imaging findings to provide an essential knowledge base for rapid diagnosis and future clinical studies.